Results 31 to 40 of about 16,460 (261)
Nanobodies that Neutralize HIV [PDF]
Vaccines, 2019 Nanobodies or VHH (variable domains of heavy-chain only antibodies) are derived from camelid species such as llamas and camels. Nanobodies isolated and selected through phage display can neutralize a broad range of human immunodeficiency virus type 1 (HIV-1) strains.
Robin A. Weiss, C. Theo Verrips
openaire +3 more sources
Nanobody-Based Bispecific Neutralizer for Shiga Toxin-Producing E.coli
, 2022 Currently, no specific therapeutics are available for foodborne Shiga toxin-producing Escherichia coli (STEC) infections that cause severe gastroenteritis and life-threatening complications of hemolytic uremic syndrome (HUS).
Roland J. Pieters +17 more
core +1 more source
Design of a humanized anti vascular endothelial growth factor nanobody and evaluation of its in vitro function [PDF]
Iranian Journal of Basic Medical Sciences, 2018 Objective(s): Nanobodies, the single domain antigen binding fragments of heavy chain-only antibodies occurring naturally in camelid sera, are the smallest intact antigen binding entities.
Fatemeh Kazemi-Lomedasht +3 more
doaj +1 more source
Recombinant expression of nanobodies and nanobody-derived immunoreagents
Protein Expression and Purification, 2020 Antibody fragments for which the sequence is available are suitable for straightforward engineering and expression in both eukaryotic and prokaryotic systems. When produced as fusions with convenient tags, they become reagents which pair their selective binding capacity to an orthogonal function.
openaire +4 more sources
Frontiers in Oncology, 2021 Breast cancer is the most common malignant cancer in women worldwide, especially in developing countries. Herceptin is a monoclonal antibody with an antitumor effect in HER2-positive breast cancer. However, the large molecular weight of Herceptin limited
Yan Yan +9 more
doaj +1 more source
Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4
BMC Cancer, 2022 Background: Antibodies and derivative drugs targeting immune checkpoints have been approved for the treatment of several malignancies, but there are fewer responses in patients with pancreatic cancer.
Shuai Hao +10 more
doaj +1 more source
Nanobody-Based Lateral Flow Immunoassay for the Rapid Detection of Aflatoxin B1 in Almond Milk
, 2022 Aflatoxin B1 (AFB1) is the most potent genotoxic and carcinogenic aflatoxin produced by Aspergillus flavus and Aspergillus parasiticus. AFB1 is considered a major concern in food safety because of its high toxicity and possible contamination of a variety
Irene Gonzalez-Garcia (13174714) +6 more
core +1 more source
Microbial Cell Factories, 2023 Background Ablynx NV, a subsidiary of Sanofi, has a long-standing focus on the development of Nanobody® molecules as biopharmaceuticals (Nanobody® is a registered trademark of Ablynx NV). Nanobody molecules are single variable domains, and they have been
Manu De Groeve +2 more
doaj +1 more source
The Therapeutic Potential of Nanobodies [PDF]
BioDrugs, 2019 Today, bio-medical efforts are entering the subcellular level, which is witnessed with the fast-developing fields of nanomedicine, nanodiagnostics and nanotherapy in conjunction with the implementation of nanoparticles for disease prevention, diagnosis, therapy and follow-up.
Ivana Jovčevska, Serge Muyldermans
openaire +2 more sources
Rapid Delivery of Nanobodies/VHHs into Living Cells via Expressing In Vitro-Transcribed mRNA
Molecular Therapy: Methods & Clinical Development, 2020 Intracellular antigen labeling and manipulation by antibodies have been long-thought goals in the field of cell research and therapy. However, a central limitation for this application is that antibodies are not able to penetrate into the cytosol of ...
Xuechen Zhou +6 more
doaj +1 more source